COVID-19: INHALE Study

COVID-19: INHALE Study

Objectives

To conduct a Stage 2 clinic trial testing a repurposed oral medication for the treatment of COVID-19.

Rationale

An effective oral repurposed medication to fight COVID-19 would dramatically change the COVID-19 crisis, particularly for individuals living in low and middle income countries with limited access to medical care. 

Project dates

April 2020 - present

Stage of work

Preliminary laboratory work is ongoing and is very promising and we are completing FDA filing to start the trial in Fall 2020.

For more information, see here.

People

Primary Contact:  Joelle Rosser

Stanford University

.   Joelle Rosser, Infectious Disease Fellow

.   Paul Bollyky, Associate Professor, Infectious Diseases

.   Nadine Nagy, Instructor, Immunology

Funding

N/A